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ABSTRACT
Introduction: Asthma is a condition characterized by eosinophilic airway inflammation and remodelling that in-
volves several pathological changes, including subepithelial fibrosis, mucus hypersecretion, smooth muscle growth, 
and vascular changes. The present study aimed to determine the effect of tHGA administered intraperitoneally in 
a chronic asthma mouse model that closely mimics the human asthma. Methods: Ovalbumin-sensitized and chal-
lenged BALB/c mice were i.p. administered with tHGA at different doses (20 and 2 mg/kg). Respiratory function 
was measured, and brochoalveolar lavage, blood and lung samples were then obtained and analyzed.  Results: The 
airways of OVA-induced mice developed increased pulmonary inflammation with increased levels of cytokines, 
chemokines, and changes in vascular permeability. Intraperitoneal administration of tHGA in OVA-induced mice 
significantly and dose-dependently inhibited the airway inflammation, production of immunoglobulin E, Th2-type 
cytokines and chemokines, and inflammatory mediators. Treatment with tHGA also significantly reduced the airway 
hyperresposiveness in response to increased methacholine doses. Conclusion: This study demonstrates that the effi-
cacy of tHGA in alleviating chronic asthmatic symptoms in mouse model improved significantly when administered 
intraperitoneally compared to oral route. Furthermore, this study also supports that tHGA has a therapeutic potential 
in chronic asthma management by acting as a cysteinyl leukotrienes (CysLT) inhibitor. 
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INTRODUCTION
Chronic asthma is a complex pulmonary disease 
exacerbated by the persistent airway inflammation, 
hyperresponsiveness, and irreversible airway 
obstruction, which cause a deterioration of lung function 
leading towards pathological airway remodelling (1,2). 
The structural remodelling in the asthmatic airways 
include the thickening of airway walls, increased 
smooth muscle cell hyperplasia/hypertrophy, mucus 
hypersecretion, and sub epithelial fibrosis (3-5). These 
pathological changes which characterize chronic 
asthma are driven by various inflammatory mediators 
secreted as a result of airway inflammation. For example, 
Th2 cytokines such as interleukin-4 (IL-4), interleukin-5 
(IL-5), and interleukin-13 (IL-13) elicit the production 
of immunoglobulin E (IgE) and eosinophil recruitment. 
IL-13 also induces mucus hypersecretion and airway 
hyperresponsiveness (6, 7). These cytokines also induce 
the inflammatory and structural cells to secrete several 
proinflammatory molecules including lipid-derived 
mediators, chemokines such as RANTES (CCL5), and 
growth factors which collectively promote subsequent 
infiltration of inflammatory cells into the airways 
(8). While Th2 cytokines promote asthmatic airway 
inflammation, evidence suggests that Th2 response is 
shifted to a Th1 response in a chronic allergic airway 
inflammation. The activation of Th1 response leads 
to the production of interferon gamma (IFN-γ). IFN- γ 
is involved in cancelling the effects of Th2 activation 
including bronchial hyperresponsiveness, mucus goblet 
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hyperplasia, and eosinophilia (9, 10, 11). 
In particular, a fibrotic cytokine, TGF-β, is thought to be 
one of the key sentinels in eliciting airway remodelling 
in asthma (12).  Kiwamoto et al. has demonstrated that 
the expression of  TGF-β in Th2-dominant GATA-3-tg 
mice increased after being repetitively challenged to 
OVA and its expression can be suppressed further by 
a leukotriene receptor antagonist, montelukast (13). 
There is also evidence showing that the recruitment and 
migration of leukocytes to the inflammatory sites require 
adhesion molecules whose expression can be induced 
by cytokines (14, 15). A previous study demonstrated 
that toluene diisocyanate (TDI)-induced asthma 
resulted in elevated expression of intracellular adhesion 
molecule (ICAM), vascular cell adhesion molecule 
(VCAM) and matrix metalloproteinase-9 (MMP-9), as 
well as increased numbers of inflammatory cells (16).  
We have previously reported that a bioactive 
component found in Melecopia ptelefolia, identified 
as 2,4,6,-trihydroxy-3-geranyl acetophenone (tHGA), 
inhibited CysLT synthesis, one of the mediators of 
asthma via the inhibition of 5-lipoxygenase (5-LOX) (19). 
CysLT synthesis requires the activation of arachidonic 
acid by 5-LOX catalysis, which was facilitated by 
5-LOX activating protein (FLAP), the key protein needed 
for the synthesis of the leukotrienes. CysLT possesses 
proinflammatory features associated in promoting 
airway eosinophilia, increasing mucus hypersecretion, 
and also acting as a potent bronchoconstrictor, which 
can lead to asthma attack (17, 18). We have also shown 
in the previous work that tHGA was able to prevent 
allergic airway inflammation in ovalbumin-sensitized 
mice by targeting CysLT synthesis (19).   Previously, we 
have reported that at least 40 mg/kg tHGA was able to 
attenuate airway inflammation in a murine model of 
chronic asthma when administered via the oral route. 
Furthermore, a higher dose (80 mg/kg) attenuated both 
airway inflammation and remodelling in that study 
(20). The present study aimed to determine whether 
lower doses of tHGA are capable of suppressing the 
airway inflammation and remodelling upon chronic 
allergic airway inflammation when administered via 
intraperitoneal route.
 
MATERIALS AND METHODS
Animals
BALB/c mice (8 - 10 weeks old, male) purchased from 
the Institute of Medical Research, Kuala Lumpur, were 
housed at the Physiology Lab Experimentation Room 
located at the Faculty of Medicine and Health Sciences, 
Universiti Putra Malaysia. The mice were acclimatized 
at 22 + 2oC with 12 h dark/light cycle and handled in 
line with the standard guidelines for the care and use 
of laboratory animals (National Research, 1996). This 
study was approved by the Animal Experimentation 
Ethics Committee, Faculty of Medicine and Health 
Sciences, Universiti Putra Malaysia.
Ovalbumin (OVA) sensitization, airway challenge and 
tHGA administration
The mice were OVA-sensitized intraperitoneally on day 
0, 7 and 14, as previously described (19). At day 21, the 
mice were exposed for 30 minutes to aerosolized 2% 
OVA (w/v) in PBS (pH 7.4) by an ultrasonic nebulizer 
(Omron, Japan) for three days per week, for six 
consecutive weeks. tHGA (2 and 20 mg/kg body weight) 
was dissolved in PBS with 1% w/v Tween 80 and 1% 
w/v DMSO and were administered intraperitoneally 10 
days before the last challenge (day 49-58), 1 hour prior 
to OVA aerosolization (Figure 1).
Figure 1: The project timeline for chronic allergic asth-
ma
The bronchoalveolar lavage fluid (BALF) analysis
Mice were culled following the methacholine challenge. 
The lungs were flushed four times with 0.9 ml cold PBS 
using 22G feeding needle cannulated from the trachea 
of the mice to recover the bronchoalveolar lavage fluid 
(BALF). The BALF samples were then centrifuged at 400 
xg at 4oC for 10 minutes. The supernatant was collected 
and stored at -80oC until required, whereas the cell 
pellet was resuspended in PBS for slide preparation. The 
cells were loaded onto the cytospin (450 µl) and spun at 
500 xg for 5 minutes at 4oC. For differential cell count, 
fixed cells were stained with the Wright’s Stain and 10 
µl of the remaining cell suspension were used for cell 
quantification by the trypan blue exclusion method. 
ELISA analysis of BALF
The concentrations of IL-4, IL-5, IL-10, IL-13, RANTES, 
and TGF-β were measured using commercial 
immunoassay kit according to the manufacturer’s 
instruction. IL-4, IL-5 and IL-10 concentrations were 
measured with ELISA kits specific for mouse IL-4, IL-
5, and IL-10 (BD Pharmingen, San Diego, CA, USA), 
whereas IL-13, RANTES, and TGF-β concentrations 
were measured using mouse DuoSet specific for each 
factor (R&D Systems). CysLT levels were measured using 
an enzyme immunoassay kit (Cayman Chemicals, Ann 
Arbor, MI, USA).
Total and OVA-Specific serum IgE measurement
Blood from each mouse was drawn through cardiac 
puncture and subjected to centrifugation to obtain 
serum. The levels of total (BD Pharmingen, San Diego, 
CA, USA) and OVA-specific serum IgE (Bio-Rad) were 
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measured by commercial ELISA kits following the 
manufacturer’s instruction. 
Lung Histology
The lungs collected were fixed in 10% formalin and 
processed accordingly to obtain sections which were 
stained with either hematoxylin and eosin (H&E), 
periodic acid shift (PAS), or Masson trichrome (MT). 
Airway inflammation of the lung was examined in 
the peribronchiol and perivascular regions. The total 
numbers of inflammatory cells in peribronchiol and 
perivascular regions were counted and averaged with 
the total number of airways per section to obtain the 
mean number of airway-infiltrated inflammatory cells. 
The goblet cell hyperplasia was determined by dividing 
PAS-positive cells by the total number of airways for the 
average number of goblet cells per slide. For the collagen 
deposition, the areas of the MT-positive stained were 
determined and divided by the area of each section to 
get the percentage of collagen deposition in the airways. 
Airway hyperresponsiveness (AHR) Measurement to 
Methacholine (Mch)
Post 24 hours of the final OVA challenge, each mice was 
placed in an unrestrained whole body plethysmograph 
(Buxco Electronics, Inc. Troy, NY) to assess the AHR 
in response to methacholine (Acetyl-β-methylcholine 
chloride, catalogue # A2251, Sigma-Aldrich). Responses 
to graded doses of methacholine (6, 12, 25, and 50 mg/
ml) were assessed by recording Penh value for 5 minutes 
to each dose. Penh values were then averaged and used 
for comparison between the experimental groups.  
Statistical analysis
Data analysis was performed using a commercial 
statistical software, Graphpad   Prism (version 5.01). 
Each data set was statistically analyzed by performing 
one-way ANOVA, followed by Dunnett’s post hoc test 
to confirm significant differences between experimental 
treatments. Data was presented as the mean + SEM and 
were considered statistically significant when P <0.05.
RESULTS
tHGA Effects on the Total and Differential Cell Count
The total and differential cell counts were performed 
on BALF samples to determine the effects of tHGA on 
the inflammatory cell infiltration into the airway. Fig.2 
shows that OVA-induced mice displayed a significant 
influx of leukocytes with increased total cell count 
and number of eosinophils compared to the naive 
group. The total cell count and number of eosinophils 
were significantly reduced upon treatment with tHGA 
at 20 mg/kg, in contrast to untreated OVA-sensitized/
challenged mice (Fig.2). 
Effects of tHGA on Th2 cytokines, chemokines, TGF-β 
and CysLT concentrations in BALF
The levels of IL-4, IL-5, IL-10, IL-13, RANTES, TGF-β, 
and CysLT in BALF samples were measured to examine 
the tHGA effect on the secretion of proinflammatory 
mediators as common indicators of airway inflammation. 
Fig.3 shows that the levels of IL-4, IL-5, IL-10, IL-13, 
RANTES, TGF-β, and CysLT in OVA-induced mice were 
significantly elevated compared to the naive group, and 
the levels were significantly reduced with 20 mg/kg 
tHGA treatment. tHGA treatment at 2 mg/kg was able to 
reduce the levels of some mediators but failed to show 
an inhibitory effect on IL-4, TGF-β, RANTES, and CysLT 
(Fig.3).
tHGA treatment effects on the total and OVA-specific 
serum IgE
The levels of total serum IgE and OVA-specific IgE 
were measured to determine the tHGA effect on OVA 
sensitization. Fig.4 shows that serum total IgE and OVA-
specific IgE in OVA-sensitized/challenged mice were 
significantly higher than naive mice, and both were 
significantly reduced when treated with tHGA at 20 mg/
kg, but not at 2 mg/kg. 
Effects of tHGA on airway cell infiltration, goblet cell 
hyperplasia and deposition of collagen
Further histopathological studies were conducted on 
Figure 2: The effects of tHGA on total cell count (A) and eosino-
phil count (B) in BALF. Trypan blue-stained cell pellets were count-
ed using a hemacytometer and differential cell counts of eosinophil 
were obtained by examining of Wright’s stained cytosmear. Data is 
expressed as mean + SEM. Significant difference from OVA-sensitized/
challenged mice, *P<0.05, **P<0.01, ***P<0.001.OVA + Zil = zileu-
ton-treated group.
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Figure 3: The effects of tHGA on Th2 cytokines, chemokines, TGF-β, 
and CysLT levels in BALF. Concentrations of (A) IL-4, (B) IL-5, (C) IL-
13, (D) IL-10, (E) TGF-β, (F) RANTES, and (G) CysLT were measured by 
ELISA. Data is expressed as mean + SEM. Significant difference from 
OVA-sensitized/challenged mice, *P<0.05, **P<0.01, ***P<0.001. 
OVA + Zil = zileuton-treated group.
Figure 4: The effects of tHGA on  (A) total IgE and (B) OVA-Specific 
IgE in serum. Values are expressed as mean + SEM. Significant dif-
ference from OVA-sensitized/challenged mice, **P<0.01, ***P<0.001.
OVA + Zil = zileuton-treated group.
the lung tissue to assess the antiasthmatic effect of 
tHGA. H & E staining of the lung tissue revealed greater 
influx of inflammatory cells within the perivascular and 
peribronchiol connective tissue in OVA-sensitized/
challenged mice (Fig.5d) than that of naive mice 
(Fig.5a). The infiltrating inflammatory cells in OVA-
induced mice was significantly reduced when treated 
with 20 mg/kg tHGA (Fig.5j). Mucus hypersecretion, an 
airway remodelling feature in a chronic asthmatic model 
is commonly indicated by goblet cell hyperplasia, as 
determined by PAS staining. Goblet cell hyperplasia 
observed in the airway lamina propria was more 
pronounced in OVA-induced mice (Fig.5e) than that 
of the PBS group (Fig.5b). In contrast, 20 mg/kg tHGA 
significantly diminished the number of goblet cell 
hyperplasia in OVA-induced mice (Fig.5k). Heightened 
deposition of airway collagen, another characteristic of 
airway remodelling in chronic asthma, was observed 
in OVA-induced murine lung tissue when assessed by 
the Masson Trichrome stain. Compared to the PBS-
treated group (Fig.5c), dense collagen deposition 
surrounding the airways and blood vessels was visible 
in the OVA-induced group (Fig.5f). Collagen deposition 
was markedly reduced by tHGA treatment at 20 mg/kg 
(Fig.5l). 
Effect of tHGA on airway function 
Airway function in conscious mice was measured as 
Penh 24 hours post the final OVA challenge. Penh 
was used as a measurement unit to indicate the airflow 
obstruction and the increase value of Penh was observed 
with increasing doses of the methacholine, an AHR 
promoter. OVA-induced mice showed elevated Penh 
value compared to those showed in the unrestrained 
naive mice (Fig.6). This might be due to the narrowing 
of the airways in response to allergen including 
ovalbumin that cause the bronchoconstriction which 
lead to respiratory dysfunction. Treatment of OVA-
induced mice with tHGA at 2 mg/kg and 20 mg/kg 
showed significant reduction of the Penh compared to 
the untreated OVA-induced mice at the 25 and 50 mg/
mL methacholine challenge doses. The positive control, 
Zileuton, a 5-LOX inhibitor also showed significantly 
reducted respiratory changes at the same doses.
DISCUSSION
In our previous study, we reported that oral administra-
tion of tHGA in a murine model of chronic asthma atten-
uates airway inflammation and airway remodelling at the 
highest dose (80 mg/kg). This study aimed to determine 
whether lower doses of tHGA treatment (2 and 20 mg/
kg) via parenteral route have therapeutic effect on air-
way inflammation and remodelling in the same animal 
model. This murine model of chronic asthma has been 
shown to reproduce important hallmarks of the human 
asthma condition (21). Warner et al. has defined airway 
remodelling as alterations in the quantity, composition, 
and organization of cells and extracellular components 
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of the airway wall (22). Accumulating evidence alludes 
that airway remodelling results in the deterioration of 
lung function and by preventing the airway remodelling, 
the severity of the disease may be attenuated (23, 24). 
Current treatments, which heavily depend on glucocor-
ticosteroid as a reliever to asthma symptoms, have been 
successful in treating airway inflammation but unable to 
reverse the remodelling of the airways. New treatments 
Figure 5: Quantitative analysis of inflammatory cell infiltration (A), goblet cell metaplasia (B), and area of collagen deposition surrounding air-
ways (C). H and E staining for PBS control group (a), OVA-sensitized/challenged mice (d), tHGA treatment at 2 mg/kg (g), and tHGA treatment at 
20 mg/kg (j) for airway inflammation. PAS staining for PBS control group (b), OVA-sensitized/challenged mice (e), tHGA treatment at 2 mg/kg (h), 
and tHGA treatment at 20 mg/kg (k) for goblet cell hyperplasia. Masson-trichrome staining for PBS control group (c), OVA-sensitized/challenged 
mice (f), tHGA treatment at 2 mg/kg (i), and tHGA treatment at 20 mg/kg (l) for collagen deposition. Data is expressed as mean + SEM. Significant 
difference from OVA-sensitized/challenged mice, *P<0.05, **P<0.01, ***P<0.001.OVA + Zil = zileuton-treated group.
Figure 6: The effect of tHGA on airway hyperresponsiveness to aer-
osolized methacholine. Values are expressed as mean + SEM. Sig-
nificant difference from OVA-sensitized/challenged mice, *P<0.05, 
**P<0.01, ***P<0.001.OVA + Zil = zileuton-treated group.
that can attenuate both airway inflammation and remod-
elling are in need to replace these current treatments. 
Our recent work showed that oral administration of 
tHGA significantly supressed both airway inflammation 
and remodelling at the highest dose tested (80 mg/kg). 
While its anti-inflammatory effect was still achieved at a 
lower dose, 40 mg/kg, the lowest dose tested (20 mg/kg) 
failed to show any signifcant effects (20). In contrast, the 
present study shows that tHGA was able to significant-
ly suppress both airway inflammation and remodelling 
at 20 mg/kg when it was administered intraperitoneally. 
Although its anti-inflammatory effects were observed at 
2 mg/kg, this dose however was not sufficient to sup-
press airway remodelling. These findings suggest that 
administration of tHGA via the parenteral route signifi-
cantly improves the efficacy of tHGA and may be a bet-
ter alternative for the treatment of chronic asthma. The 
lower efficacy of tHGA via oral administration is likely 
attributed to its low bioavailability due incomplete ab-
sorption or high first pass effect. In the present study, 
OVA-sensitized/challenged mice showed greater airway 
inflammation and remodelling in comparison to the PBS 
control group. In particular, OVA-sensitized/challenged 
mice displayed increased airway hyperresponsiveness, 
greater eosinophil infiltration, hypersecretion of mucus, 
and collagen deposition in the airways. Such remodel-
ling of the airway was also associated with increased 
levels of Th2 cytokines, chemoattractant molecules, and 
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growth factors. Th2 cytokines such as IL-4, IL-5, and IL-
13 are secreted by activated T helper type 2 cells. tHGA, 
a nonmetal chelator compound has been reported to al-
leviate the synthesis of Th2 cytokines in the acute al-
lergic asthma mouse model. The present study demon-
strates that similar effects of tHGA were observed in a 
murine model of chronic allergic asthma. As previously 
mentioned, reduced levels of Th2 cytokines may possi-
bly be due to tHGA’s ability to supress 5-LO/CysLT syn-
thesis. Th2 cytokines and CysLT has been suggested to 
positively and mutually modulate the activation of one 
another in which CysLT production was regulated by 
the Th2 cytokines via the coordination of 5-LOX nuclear 
import and LTC4 synthase expression (13, 25). 
CysLT, however, is known to take part in the remod-
elling of airways via processes unrelated to inflamma-
tion (13). It directly promotes airway smooth muscle 
hyperplasia and hyperthrophy and increases collagen 
synthesis by lung fibroblasts (26). Th2 cytokines, in par-
ticular IL-4 and IL-13, secreted by infiltrating inflamma-
tory cells can induce TGF-β1 production by bronchial 
epithelial cells, a factor that is able to directly convert 
subepithelial fibroblasts into myofibroblasts or through 
arginase (27). Blocking TGF-β activity was shown to in-
hibit remodelling phenotypes that include epithelial cell 
shedding, airway smooth muscle cell hypertrophy, and 
hyperplasia, hypersecretion of mucus, and angiogenesis 
in a murine asthmatic model (28). Espinosa et al. has 
demonstrated a synergism correlation between CysLT 
and TGF-β, which suggests that LTD4 alone was inca-
pable of supporting smooth muscle cell proliferation in 
the absence of TGF-β1 or IL-13, two factors shown to 
increase the expression of CysLT1 receptor (26). Thus, 
we believe that the downregulation of CysLT and TGF-β 
expression may partly mediate the inhibitory effect of 
tHGA on sub epithelial fibrosis . 
The effects of tHGA on chemoattractant molecules 
may also be related to the inhibition of CysLT synthe-
sis. Mariko et al. proved that the effector functions of 
eosinophils were effectively induced by joint exposure 
to ICAM-1 or VCAM-1 and CysLT. This combinatory ex-
posure significantly induced eosinophil O2 – generation 
that also activate the respiratory burst or degranulation 
(29). Findings from Hemelaers et al. further suggest active 
participation of CysLT in the chemotaxis of eosinophils 
in the asthmatic airway as they observed the inhibition 
of chemotactic activity of sputum eosinophils of both 
corticosteroid-naive and corticosteroid-treated asth-
matic patients when treated with a leukotriene receptor 
antagonist, montelukast (30). Nagata et al. meanwhile 
reported that LTD4 was shown to increase the CD11b 
and CD18 expression, which enhances eosinophil ad-
hesion to ICAM-1. Interaction of IL-4 with very late an-
tigen-4 (VLA-4) upregulated the expression of VCAM-1, 
thus promoted the recruitment of eosinophils (31, 32). 
RANTES (CCL5) is among the chemokines that can be 
produced in substantial amounts by structural cells 
such as fibroblasts, epithelial, and endothelial cells that 
can contribute to airway remodelling once activated. 
RANTES, a chemotactic factor for T cells, eosinophils, 
basophils, is a key player in the leukocyte recruitment 
into the sites of inflammation. This study demonstrates 
a significant decrease in the RANTES levels in OVA-in-
duced mice when treated with tHGA compared to un-
treated OVA-induced group. This may be due to tHGA 
ability to supress Th2 cytokines secretion which subse-
quently inhibit the activation of RANTES expression. 
In this study, we reported that tHGA was able to reduce 
the CysLT, IgE, and OVA-specific serum IgE levels in 
OVA-sensitized/challenged mice in a dose dependent 
manner when administered via intraperitoneal route. In 
contrast, the positive control Zileuton did not show such 
inhibitory effect on these parameters in serum. Although 
zileuton is a well-known oral active inhibitor of 5-LOX 
which inhibits CysLT (33), findings from this study sug-
gest that Zileuton may be less effective at reducing IgE 
levels when administered via intraperitoneal route. In 
comparison to Zileuton, our findings suggest that while 
tHGA may be an orally active inhibitor of 5-LOX,  the ef-
ficacy of tHGA in reducing the cysLT, IgE and OVA-spe-
cific serum IgE levels was improved when it was admin-
istered to the mice intraperitoneally. 
CONCLUSION
This study demonstrates the therapeutic effects of tHGA in 
chronic allergic airway inflammation when administered 
via intraperitoneal route, mainly through the inhibition 
of eosinophil infiltration, airway hyperresponsiveness, 
goblet cell hyperplasia, Th2 cytokines expression, and 
subepithelial fibrosis. This study also highlights that 
different administration routes indeed affect the doses 
of tHGA required to attenuate the chronic asthmatic 
symptoms. Specifically, lower dose of tHGA is sufficient 
to attenuate airway inflammation and remodeling 
in murine model of chronic asthma with parenteral 
administration compared to oral administration.  While 
this study supports the therapeutic potential of tHGA in 
treating chronic asthma, further studies are adamant in 
elucidating the mechanism by which tHGA exerts its 
effects on airway inflammation and remodelling. 
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